Cassandra Willyard If authorized, molnupiravir would be the first oral treatment for COVID-19.Credit: Merck & Co Inc/Handout/Reuters The pharmaceutical firm Merck announced last week that an antiviral pill it’s developing can cut hospitalizations and deaths among people with COVID-19 by half. The results haven’t yet been peer reviewed. But if the drug candidate, molnupiravir, is...
Tag: <span>COVID Drug</span>
Post
Molecular mechanisms of COVID drug candidate Molnupiravir unraveled
by Max Planck Society The antiviral drug candidate molnupiravir (yellow) is incorporated into the viral RNA, where it leads to mutations (purple) that ultimately prevent the virus from replicating. Credit: MPI f. Biophysical Chemistry/ Florian Kabinger, Christian Dienemann, and Patrick Cramer The United States recently secured 1.7 million doses of a compound that could help to...
Post
Hydroxychloroquine: Possible COVID Drug Can Be Toxic to Retinas
Brianne N. Hobbs, OD; Kaila M. Osmotherly, OD Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. As we await evidence from multiple ongoing trials of hydroxychloroquine (HCQ) for the treatment of COVID-19, clinicians have had to make do with conflicting reports regarding its potential efficacy. Although HCQ is one of the...